Cancer Therapy Supplement Natural Powder CAS 319460-85-0 Axitinib


Quick Detail:

Product Name	Axitinib
Synonyms	AXITINIB; Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-; N-M ETHYL-2-{[3-((E)-2-PYRIDIN-2-YLVINYL)-1H-INDAZOL-6-YL]SULFANYL}BENZAMIDE; N Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; AVERMECTINB; Axitinib for research; AG 013736; N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide
CAS NO	319460-85-0
MF	C22H18N4OS
MW	386.47
Storage	Shading, confined preservation
Assay	> 99%
Grade	Pharmaceutical Grade
Character	Off-White Solid
Drug Class	Injectable Anabolic Androgenic Steroid
Brand	NJBN STEROID
Delivery time	Within 24 hours upon receipt of payment
Shipping	EMS, DHL, TNT, FedEx, UPS
Usage	Axitinib is a tyrosine kinase inhibitor. Axitinib is used in cancer therapy.

Product Description:

1. Axitinib is also called by its brand name Inlyta. It is a type of drug called a tyrosine kinase inhibitor, which is a cancer growth blocker. It blocks certain proteins called tyrosine kinases from acting on cells. Tyrosine kinases signal to cancer cells to grow. Axitinib blocks different types of tyrosine kinase and is called a multi kinase inhibitor. It stops cancer cells forming blood vessels, which the cancer needs in order to grow. This is called anti angiogenesis treatment. Axitinib is a treatment for advanced kidney cancer. You may also have it as part of a clinical trial for other cancers including soft tissue sarcoma and thyroid cancer.
2. Axitinib interferes with the growth of some cancer cells. Axitinib is used to treat advanced kidney cancer. Axitinib is usually given after other cancer medicine has been tried without success. Axitinib may also be used for purposes not listed in this medication guide. Axitinib dose-dependently inhibits tumor growth in MV522 with ED50 value of 8.8 mg/kg twice daily, based on the relationship between dose and the corresponding TGI (tumor growth inhibition).
3. Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma. Axitinib therapy is commonly associated with transient elevations in serum aminotransferase that are generally mild and asymptomatic. Axitinib has yet to be linked to instances of clinically apparent acute liver injury.

Applications:

1. Axitinib is indicated for kidney cancer. Axitinib is a kinase inhibitor shown to inhibit the vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3) implicated in angiogenesis and tumor growth leading to cancer progression. Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
2. The AXIS trial was a phase 3 randomized trial that showed the efficacy of this drug. In this study it was showed that axitinib may increase progression-free survival (PFS) compared to sorafenib in patients with metastatic renal cell carcinoma who previously had failed to first-line therapy with sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. 389 patients (54%) had received 1 prior sunitinib-based therapy, 251 patients (35%) had received 1 prior cytokine-based therapy (interleukin-2 or interferon-alfa), 59 patients (8%) had received 1 prior bevacizumab-based therapy, and 24 patients (3%) had received 1 prior temsirolimus-based therapy. The baseline demographic and disease characteristics were similar between the axitinib and sorafenib groups with regard to age (median 61 years), gender (72% male), race (75% white and 21% Asian), and Eastern Cooperative Oncology Group (ECOG) performance status (55% 0, 45% 1), and histology (99% clear cell)

this study they recruited 723 patients (median age 61 years) with metastatic renal cell carcinoma; they were randomized (1:1) without blinding to axitinib 5mg (N = 361) twice daily versus sorafenib 400mg (N = 362) twice daily; allocation concealment was not done. All patients had renal clear-cell carcinoma that progressed despite first-line therapy with sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Increased Axitinib dose was allowed for patients without hypertension or adverse reactions
4. Progression free survival (PFS) was defined as time from randomization to either first documentation of disease progression (per independent blinded radiology review of images) or death due to any cause. The median duration of axitinib therapy was 6.4 months and sorafenib therapy was 5 months. Disease progression or relapse occurred in 160 patients (44%) in axitinib group and 180 patients (50%) in sorafenib group. There was a statistically significant advantage for axitinib over sorafenib for the endpoint of PFS. There was no statistically significant difference between the arms in OS. Comparing axitinib versus sorafenib in intention-to-treat analysis, the PFS was 6.7 months in the axitinib group versus 4.7 months in the sunitinib group; hazard ratio was 0.665 (95% CI 0.544-0.812); one-sided P < 0.0001, and the objective tumor response was 19% versus 9% respectively (P = 0.0001, NNT 10)

Hi, I'm teresa, everybody is taking the similar words, what I? Want to say is: Just give me a? Chance, Just have a? Try on me, maybe you will get a? Big surprise on me, come to join us, Buddy!